Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Loss of Smell in Early Alzheimer’s Linked to Immune System Attacks on Olfactory Nerve Fibers
For decades, the clinical hallmark of Alzheimer’s disease has been the progressive erosion of memory and cognitive function. However, emerging…
Read More
Salk Institute Researchers Identify BCL6 Protein as Key to Preventing Muscle Loss During GLP-1 Assisted Weight Management and Aging
The pharmaceutical landscape of the 2020s has been defined by the meteoric rise of GLP-1 receptor agonists. Drugs such as…
Read More
US Government Assumes Full Cost of Weight Loss Drugs for Medicare Beneficiaries Through Extended GLP-1 Bridge Program Amidst Insurer Hesitation
The Centers for Medicare & Medicaid Services (CMS) has announced a significant extension of its Medicare GLP-1 Bridge program, shifting…
Read More
The Alarming Rise of Unregulated Weight Loss Medications in the UK: A Public Health Crisis in the Making
British people are increasingly turning to potentially unregulated weight loss medications as drug prices climb and waits for prescriptions lengthen.…
Read More
University of Hong Kong Researchers Identify Biological Exercise Sensor to Combat Osteoporosis and Bone Loss in Aging Populations
Researchers from the Department of Medicine at the School of Clinical Medicine, LKS Faculty of Medicine, University of Hong Kong…
Read More
UC San Francisco Researchers Identify Biological Link Between Gut Immune Response and Brain-Mediated Appetite Loss
In a breakthrough study that bridges the gap between immunology and neuroscience, researchers at the University of California, San Francisco…
Read More
Novo Nordisk’s triple agonist UBT251 delivered up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, has announced promising results from a Phase 2 trial of…
Read More
Immune System Response in the Brain Identified as Primary Cause for Early Olfactory Loss in Alzheimer’s Disease
A groundbreaking study conducted by researchers at the German Center for Neurodegenerative Diseases (DZNE) and Ludwig-Maximilians-Universität München (LMU) has revealed…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial.
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read MoreYOU MAY HAVE MISSED
